Conformis Announces License Agreement with Paragon 28
April 19 2021 - 4:30PM
Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered
into a license agreement with Paragon 28, Inc., granting Paragon 28
a non-exclusive license under a subset of Conformis’ U.S. patents
for the use of patient-specific instruments with off-the-shelf
implants in Paragon 28’s APEX 3D™ Total Ankle Replacement System.
“We are pleased to reach this agreement with Paragon 28,
enabling it to incorporate our patient-specific instrument
technology in its anticipated total ankle replacement offering,”
said Mark Augusti, President and Chief Executive Officer. “We
believe that this latest license agreement further demonstrates the
broad applicability and clinical appeal of Conformis’
technology.”
About Conformis, Inc.
Conformis is a medical technology company that uses its
proprietary iFit® Image-to-Implant® technology platform to develop,
manufacture, and sell joint replacement implants and instruments
that are individually sized and shaped, which we refer to as
personalized, individualized, or sometimes as customized, to fit
each patient’s unique anatomy. Conformis offers a broad line of
sterile, personalized knee and hip implants and single-use
instruments delivered to hospitals and ambulatory surgical centers.
Conformis owns or exclusively in-licenses issued patents and
pending patent applications that cover personalized implants and
patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com. To receive
future releases in e-mail alerts, sign up
at ir.conformis.com.
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this press release about our future expectations,
plans and prospects, including statements about the settlement of
patent disputes and the collection of payments, as well as other
statements containing the words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,”
“might,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “will,” or “would” and similar expressions, constitute
forward-looking statements within the meaning of the safe harbor
provisions of The Private Securities Litigation Reform Act of 1995.
You should not place undue reliance on our forward-looking
statements. Actual results could differ materially from the
expectations disclosed in the forward-looking statements we make as
a result of a variety of risks and uncertainties, including risks
and uncertainties described in the “Risk Factors” sections of our
public filings with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent our views as of the date hereof. We anticipate
that subsequent events and developments may cause our views to
change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should
not be relied upon as representing our views as of any date
subsequent to the date hereof.
CONTACT:
Investor Contact
ir@conformis.com
+1 (781) 374-5598
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2023 to Apr 2024